

2023 Europe Tumor Markers Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers-A 38-Country Analysis-2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Segment Forecasts for over 40 Individual Cancer Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

https://marketpublishers.com/r/220FCEE96A50EN.html

Date: March 2023

Pages: 0

Price: US\$ 15,600.00 (Single User License)

ID: 220FCEE96A50EN

# **Abstracts**

This new 38-country report from LeadingMarketResearch.com is available by country, market segment, section, or individual test.

The report is available by section, and can be customized to specific information needs and budget.

This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.

The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.

Rationale



The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

## Country Analyses

Albania, Austria, Belarus, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Tests

Oncogenes - Biochemical Markers - Growth Factors - Colony Stimulating Factors - Hormones - Immunohistochemical Stains - Lymphokines

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic



Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

Sales and market shares of major cancer diagnostic product suppliers in major countries by individual test.

Five-year test volume and sales forecasts for major cancer diagnostic assays.

#### Instrumentation Review

Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

## Technology Assessment

Assessment of latest technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies.

Companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

#### Competitive Strategies

Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

The companies analyzed in the report include:

Abbott, Affymetrix, Beckman Coulter/Danaher/Cepheid, Becton Dickinson, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujifilm Wako,



Fujirebio, Grifols, Hologic, Leica Biosystems, Perkin Elmer, Qiagen, QuidelOrtho, Roche, Siemens Healthineers, Takara Bio, Thermo Fisher and others.



## **Contents**

#### I. INTRODUCTION

#### II. WORLDWIDE MARKET OVERVIEW

#### **III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES**

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

## IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

#### V. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

#### VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

## VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

- A. Cancer Statistics and Etiology
  - 1. Breast Cancer
  - 2. Lung Cancer
  - 3. Colon and Rectum Cancer
  - 4. Prostate Cancer



- 5. Stomach Cancer
- 6. Leukemia
- 7. Lymphoma
- 8. Oral Cancer
- 9. Skin Cancer
- 10. Uterine Cancer
- 11. Ovarian Cancer
- 12. Bladder Cancer
- B. Major Current and Emerging Cancer Diagnostic Tests
  - 1. Introduction
  - 2. Tumor Marker Classification
  - 3. ACTH
  - 4. Alpha-Fetoprotein (AFP)
  - 5. Beta-2 Microglobulin
  - 6. CA 15-3/27.29
  - 7. CA 19-9
  - 8. CA-125
  - 9. Calcitonin
  - 10. Carcinoembrionic Antigen (CEA)
  - 11. Estrogen and Progesterone Receptors
  - 12. Ferritin
  - 13. Gastrin
  - 14. Human Chorionic Gonadotropin (HCG)
  - 15. Insulin
  - 16. NSE
  - 17. Occult Blood
  - 18. PAP Smear/HPV
  - 19. Prostatic Acid Phosphatase (PAP)
  - 20. Prostate-Specific Antigen (PSA)
  - 21. Squamous Cell Carcinoma Antigen (SCC)
  - 22. T and B Lymphocytes
  - 23. TdT
  - 24. Thyroglobulin
  - 25. Tissue Polypeptide Antigen (TPA)
  - 26. Biochemical Tumor Markers
  - 27. Oncogenes

Abl/abl-bcr

AIB1

BCL-2



|              |                  | $\sim$ | Λ  | - 4 |
|--------------|------------------|--------|----|-----|
| $\mathbf{H}$ | $\boldsymbol{-}$ |        | /\ | 7   |
| 1 )          | ı 🔪              | ٠,     | _  |     |

**CD44** 

C-fos

C-myb

C-myc

CYP-17

Erb-B

HPC1

N-myc

P40

P51

P53

PIK3CA

PTI-1

Ras

Reg

Sis

Src and others

28. Polypeptide Growth Factors

Basic Fibroblast Growth Factor

Beta-TGF

Cachectin (TNT)

Calmodulin

**ECFR** 

Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

Alpha-Interferon

**B Cell Growth Factors** 

B Cell Growth Factor (BCGF)

Gamma-Interferon

Interleukin-1 (IL-1)

Macrophage Activating Factor

32. Immunohistochemical Stains



# 33. Emerging Tumor Markers

N-Acetylglucosamine

Actin

Alpha-Actin

**Antineuronal Antibodies** 

7B2

B72.3

Bax

BCD-F9

BLCA-4

Blood Group Antigens A,B,H

CA

CA 72-4/TAG-72

CA

CA-242

CA-549

**CAM** 

CAR-3

Cathepsin-D

Chromogranin A and B

Cluster 1 Antigen

Cluster-5/5A Antigen

**CTA** 

**CU18** 

**DR-70** 

DU-PAN-2

**Endometrial Bleeding Associated Factor** 

Endostatin

Epithelial Membrane Antigen

Feulgen Hydrolysis

Fibronectin

**FSH** 

(1->3)-L-fucosyltransferase

Gastrin-Releasing Peptide (GRP)

GDCFP-15

Glucagon

Glycoamines

H23

Her-2



Human Carcinoma Antigen

**HPA** 

HSP27

Intermediate Filaments

Cytokeratins/CK18/Cyfra 21-1

Desmin

Gliofibrillary Acid Protein

Neurofilaments

Vimentin

KΑ

Kinases

**KP16D3** 

LAI

Leukocyte Common Antigen

Lewis Antigens

Lysophosphatidic Acid (LPA)

Ma 695/Ma

MABDF3

MAG

ME1

Minactivin

MN/CA9

MSA

Mucin Cancer Antigen (MCA)

Multiple Tumor Suppressor

Myosin

**NEA-130** 

NMP22

OA-519

**Opioid Peptides** 

P-glycoprotein

Pancreatic Oncofetal Antigen (POA)

Placental Lactogen

PR92

Proliferative Index, Ki-67

Px

RB Inactivation/Deletion

Ret

**SCCL** 



Selectin

Sialic Acid

Sialyl SSEA-1/SLX

**SN10** 

Somatostatin

TA-90

**TABA** 

Tachykinin

TAG

**TPS** 

Troponin

**Tubulin** 

**VCAM** 

**VEGF** 

Villen and others

- C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
- D. Current and Emerging Cancer Diagnostic Technologies
  - 1. Monoclonal and Polyclonal Antibodies
  - 2. Immunoassays
  - 3. Molecular Diagnostics
  - 4. Chromosome Analysis
    - a. Chronic Myelogenous Leukemia (CML)
    - b. Acute Myeloid Leukemia (AML)
    - c. Acute Lymphoblastic Leukemia (ALL)
    - d. Malignant Lymphomas Lymphoid Malignancies
    - e. Chronic Lymphocytic Leukemia (CLL)
    - f. Solid Cancers
    - g. Chromosomal Translocation and Oncogenes
  - 5. Artificial Intelligence
  - 6. Flow Cytometry
  - 7. Two Dimensional Gel Electrophoresis (2-DGE)
  - 8. Biosensors
  - 9. Competing/Complementing Technologies
- E. Personal Testing

# VIII. 38-COUNTRY MARKET ANALYSES: TEST VOLUME AND SALES FORECASTS, SUPPLIER SHARES

## IX. COMPETITIVE PROFILES



The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:

Abbott

Affymetrix

Beckman Coulter/Danaher/Cepheid

**Becton Dickinson** 

bioMerieux

Bio-Rad

DiaSorin

Eiken Chemical

Elitech Group

Enzo Biochem

Fujifilm Wako

Fujirebio

Grifols

Hologic

Leica Biosystems

PerkinElmer

Qiagen

QuidelOrtho

Roche

Siemens Healthineers

Takara Bio

Thermo Fisher and others



#### I would like to order

Product name: 2023 Europe Tumor Markers Testing Market-High-Growth Opportunities for Cancer

Diagnostic Tests and Analyzers-A 38-Country Analysis-2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Segment Forecasts for over 40 Individual Cancer Markers, Latest Technologies and Instrumentation Pipeline, Emerging

Opportunities for Suppliers

Product link: https://marketpublishers.com/r/220FCEE96A50EN.html

Price: US\$ 15,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/220FCEE96A50EN.html">https://marketpublishers.com/r/220FCEE96A50EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

| Last name:    |                           |
|---------------|---------------------------|
| Email:        |                           |
| Company:      |                           |
| Address:      |                           |
| City:         |                           |
| Zip code:     |                           |
| Country:      |                           |
| Tel:          |                           |
| Fax:          |                           |
| Your message: |                           |
|               |                           |
|               |                           |
|               |                           |
|               | **All fields are required |
|               | Custumer signature        |

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>



To place an order via fax simply print this form, fill in the information below and fax the completed form to  $+44\ 20\ 7900\ 3970$